Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Stroke Neurologist’s Perspective on the New Endovascular Trials

View through CrossRef
Before December 2014, the only proven effective treatment for acute ischemic stroke was recombinant tissue-type plasminogen activator (r-tPA). This has now changed with the publication of the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN), Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times (ESCAPE), Extending the Time for Thrombolysis in Emergency Neurological Deficits—Intra-Arterial (EXTEND IA), Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment Trial (SWIFT PRIME), and Randomized Trial of Revascularization With the Solitaire FR Device Versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting Within Eight Hours of Symptom Onset (REVASCAT) studies. We review the main results of these studies and how they inform stroke patient management going forward. The main take home points for neurologists are (1) intra-arterial thrombectomy is a potently effective treatment and should be offered to patients who have documented occlusion in the distal internal carotid or the proximal middle cerebral artery, have a relatively normal noncontrast head computed tomographic scan, severe neurological deficit, and can have intra-arterial thrombectomy within 6 hours of last seen normal; (2) benefits are clear in patients receiving r-tPA before intra-arterial thrombectomy; r-tPA should not be withheld if the patient meets criteria, and benefit in patients who do not receive r-tPA or have r-tPA exclusions requires further study; and (3) these favorable results occur when intra-arterial thrombectomy is performed in an endovascular stroke center by a coordinated multidisciplinary team that extends from the prehospital stage to the endovascular suite, minimizes time to recanalization, uses stent-retriever devices, and avoids general anesthesia. In conclusion, stroke teams, including practicing neurologists caring for patients with stroke should now provide the option for intra-arterial thrombectomy for a subset of patients with acute stroke.
Ovid Technologies (Wolters Kluwer Health)
Title: Stroke Neurologist’s Perspective on the New Endovascular Trials
Description:
Before December 2014, the only proven effective treatment for acute ischemic stroke was recombinant tissue-type plasminogen activator (r-tPA).
This has now changed with the publication of the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN), Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times (ESCAPE), Extending the Time for Thrombolysis in Emergency Neurological Deficits—Intra-Arterial (EXTEND IA), Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment Trial (SWIFT PRIME), and Randomized Trial of Revascularization With the Solitaire FR Device Versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting Within Eight Hours of Symptom Onset (REVASCAT) studies.
We review the main results of these studies and how they inform stroke patient management going forward.
The main take home points for neurologists are (1) intra-arterial thrombectomy is a potently effective treatment and should be offered to patients who have documented occlusion in the distal internal carotid or the proximal middle cerebral artery, have a relatively normal noncontrast head computed tomographic scan, severe neurological deficit, and can have intra-arterial thrombectomy within 6 hours of last seen normal; (2) benefits are clear in patients receiving r-tPA before intra-arterial thrombectomy; r-tPA should not be withheld if the patient meets criteria, and benefit in patients who do not receive r-tPA or have r-tPA exclusions requires further study; and (3) these favorable results occur when intra-arterial thrombectomy is performed in an endovascular stroke center by a coordinated multidisciplinary team that extends from the prehospital stage to the endovascular suite, minimizes time to recanalization, uses stent-retriever devices, and avoids general anesthesia.
In conclusion, stroke teams, including practicing neurologists caring for patients with stroke should now provide the option for intra-arterial thrombectomy for a subset of patients with acute stroke.

Related Results

Iranian stroke model-how to involve health policymakers
Iranian stroke model-how to involve health policymakers
Stroke in Iran, with more than 83 million population, is a leading cause of disability and mortality in adults. Stroke has higher incidence in Iran comparing the global situation a...
HIPERTENSI, USIA, JENIS KELAMIN DAN KEJADIAN STROKE DI RUANG RAWAT INAP STROKE RSUD dr. M. YUNUS BENGKULU
HIPERTENSI, USIA, JENIS KELAMIN DAN KEJADIAN STROKE DI RUANG RAWAT INAP STROKE RSUD dr. M. YUNUS BENGKULU
Hypertension, Age, Sex, and  Stroke  Incidence In Stroke Installation Room RSUD dr. M. Yunus BengkuluABSTRAKStroke adalah gejala-gejala defisit fungsi susunan saraf yang diakibatka...
Deciphering Popliteal Artery Aneurysm Patient Diversity: Insights From a Cluster Analysis of the POPART Registry
Deciphering Popliteal Artery Aneurysm Patient Diversity: Insights From a Cluster Analysis of the POPART Registry
Background Popliteal artery aneurysms (PAAs) are the most common peripheral aneurysm. However, due to its rarity, the cumulative body of evidence regarding patient patt...
Scoping Review of Existing Stroke Guidelines; Argument for a Value-Added Change
Scoping Review of Existing Stroke Guidelines; Argument for a Value-Added Change
Abstract Background and Purpose Stroke represents one of the most important causes of morbidity ( eighty million patients with ...
Abstract 3387: Community Education: A Statewide Effort
Abstract 3387: Community Education: A Statewide Effort
Background: The fourth leading cause of death for all Iowans is stroke. Southeast Iowa has higher mortality rates from stroke than northeast Iowa which indicates a geog...
Heterogeneity among women with stroke: health, demographic and healthcare utilization differentials
Heterogeneity among women with stroke: health, demographic and healthcare utilization differentials
Abstract Background Although age specific stroke rates are higher in men, women have a higher lifetime risk and are more likely to die from a stroke...
Systematic Review of Existing Stroke Guidelines: Case for a Change
Systematic Review of Existing Stroke Guidelines: Case for a Change
Background and Purpose. Stroke represents one of the most important causes of morbidity (Just over hundred million patients with disabling of ongoing effects of...

Back to Top